IBD & Colon Cancer Risk: What Science Says About Prevention & Aspirin

Inflammatory Bowel Disease (IBD)—including Ulcerative Colitis (UC) and Crohn’s Disease—significantly elevates the long-term risk of developing colitis-associated colorectal cancer (CAC) through a distinct "inflammation-dysplasia-carcinoma" pathway . While historical data indicated cumulative 30-year cancer risks of up to 18%, modern population studies show rates dropping closer to 7% thanks to targeted biologic therapies, treat-to-target strategies, and structured surveillance colonoscopies . In this video, we break down: Primary Risk Factors: How disease extent (such as pancolitis), disease duration (&8 years), persistent mucosal inflammation, and coexisting primary sclerosing cholangitis (PSC) alter individual cancer risk . Molecular Drivers & Microbiome: The role of early TP53 mutations, oxidative stress, and gut microbial dysbiosis in accelerating tissue damage . Chemoprevention Debates: The established protective role of 5-aminosalicylates (mesalamine) alongside recent observational research evaluating daily low-dose aspirin . Disclaimer: This video is for educational purposes only and should not replace personalized medical advice from your gastroenterologist. Hashtags: #InflammatoryBowelDisease #UlcerativeColitis #ColorectalCancer #Gastroenterology #IBDResearch #ColonCancerPrevention #MedicalEducation #Colonoscopy #AspirinResearch